Low risk
Reduces the probability of the conditions analysed, but does not exclude them completely and does not assess every disease.
Expanded non-invasive prenatal screening
Laboratorio Calderón NI/+
Askabide provides the expanded NI/+ test. It analyses cell-free DNA in maternal blood to estimate the risk of chromosome conditions. It is screening, not a definitive diagnosis.
- Obstetric consultation
- Advanced ultrasound
- Laboratory and screening
- Late-pregnancy monitoring
- Nutrition
Complementary follow-upAskabide + Osakidetza · birth at the reference hospital
What expanded NI/+ analyses
- Aneuploidies across all chromosomes.
- Trisomies 21, 18, 13 and 9 listed by the laboratory.
- Sex chromosome aneuploidies: 45,X; 47,XXY; 47,XXX and 47,XYY.
- Deletions and duplications greater than 7 Mb.
- Optional fetal sex included in the same study.
When it can be performed
Laboratorio Calderón states that the test is available from ultrasound-confirmed week 10. Before collection, gestational age, pregnancy type and circumstances that may affect testing are reviewed.
Specific conditions should be confirmed in twin pregnancy, egg donation and other particular situations.
What the result means
High risk
Requires medical explanation and, where appropriate, confirmation with a diagnostic invasive test.
No result
Insufficient fetal fraction or another quality criterion may require a repeat sample or alternative strategy.
What must not be promised
The test cannot state that the fetus is “completely healthy”. It does not replace ultrasound, first-trimester screening, the anomaly scan or indicated diagnostic testing.
A broader panel provides more information, but performance and predictive values are not identical for every condition.
NI/+ and the specific fetal sex test
NI/+ can include fetal sex, but Askabide also offers a specific test for patients who only want that information. They answer different questions.
Fetal sex in maternal blood
A specific test separate from chromosome screening.
Open informationClinical sources
General information only. It does not replace an individual medical assessment or recommendation.
Reviewed 19 August 2026